Drug intelligence / Profile preview

RA06GB

Development stage: Preclinical
Lead developer: Remab Therapeutics
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

RA06GB is a preclinical-stage polymeric conjugate being developed by Remab Therapeutics for the treatment of Graves-Basedow disease (autoimmune hyperthyroidism). The drug is designed to selectively remove pathogenic anti-thyroid stimulating hormone receptor (TSHR) antibodies, also known as thyrotropin receptor antibodies (TRAb), which aberrantly activate the thyroid gland and cause hyperthyroidism. By targeting and removing these harmful autoantibodies from the circulation, RA06GB aims to restore normal hormonal levels. This approach represents a novel therapeutic strategy compared to standard treatments like antithyroid drugs, radioiodine ablation, and surgery.

Targets

TRAb (Thyrotropin receptor antibody)

Beyond the preview

Go deeper on RA06GB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RA06GB.

Explore the full profile